1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Patient-derived Xenograft (PDX) Models Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Mouse Model
1.2.3 Rat Model
1.3 Market by Application
1.3.1 Global Patient-derived Xenograft (PDX) Models Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Preclinical Drug development
1.3.3 Biomarker Analysis
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Patient-derived Xenograft (PDX) Models Market Perspective (2018-2029)
2.2 Patient-derived Xenograft (PDX) Models Growth Trends by Region
2.2.1 Global Patient-derived Xenograft (PDX) Models Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Patient-derived Xenograft (PDX) Models Historic Market Size by Region (2018-2023)
2.2.3 Patient-derived Xenograft (PDX) Models Forecasted Market Size by Region (2024-2029)
2.3 Patient-derived Xenograft (PDX) Models Market Dynamics
2.3.1 Patient-derived Xenograft (PDX) Models Industry Trends
2.3.2 Patient-derived Xenograft (PDX) Models Market Drivers
2.3.3 Patient-derived Xenograft (PDX) Models Market Challenges
2.3.4 Patient-derived Xenograft (PDX) Models Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue
3.1.1 Global Top Patient-derived Xenograft (PDX) Models Players by Revenue (2018-2023)
3.1.2 Global Patient-derived Xenograft (PDX) Models Revenue Market Share by Players (2018-2023)
3.2 Global Patient-derived Xenograft (PDX) Models Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Patient-derived Xenograft (PDX) Models Revenue
3.4 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio
3.4.1 Global Patient-derived Xenograft (PDX) Models Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Patient-derived Xenograft (PDX) Models Revenue in 2022
3.5 Patient-derived Xenograft (PDX) Models Key Players Head office and Area Served
3.6 Key Players Patient-derived Xenograft (PDX) Models Product Solution and Service
3.7 Date of Enter into Patient-derived Xenograft (PDX) Models Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Patient-derived Xenograft (PDX) Models Breakdown Data by Type
4.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Type (2018-2023)
4.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Type (2024-2029)
5 Patient-derived Xenograft (PDX) Models Breakdown Data by Application
5.1 Global Patient-derived Xenograft (PDX) Models Historic Market Size by Application (2018-2023)
5.2 Global Patient-derived Xenograft (PDX) Models Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
6.2 North America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
6.4 North America Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
7.2 Europe Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
7.4 Europe Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
8.2 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2018-2023)
8.4 Asia-Pacific Patient-derived Xenograft (PDX) Models Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
9.2 Latin America Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
9.4 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size (2018-2029)
10.2 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2018-2023)
10.4 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Crown Bioscience
11.1.1 Crown Bioscience Company Detail
11.1.2 Crown Bioscience Business Overview
11.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Introduction
11.1.4 Crown Bioscience Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.1.5 Crown Bioscience Recent Development
11.2 Champions Oncology
11.2.1 Champions Oncology Company Detail
11.2.2 Champions Oncology Business Overview
11.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Introduction
11.2.4 Champions Oncology Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.2.5 Champions Oncology Recent Development
11.3 Wuxi Apptec
11.3.1 Wuxi Apptec Company Detail
11.3.2 Wuxi Apptec Business Overview
11.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Introduction
11.3.4 Wuxi Apptec Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.3.5 Wuxi Apptec Recent Development
11.4 The Jackson Laboratory
11.4.1 The Jackson Laboratory Company Detail
11.4.2 The Jackson Laboratory Business Overview
11.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Introduction
11.4.4 The Jackson Laboratory Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.4.5 The Jackson Laboratory Recent Development
11.5 EPO Berlin-Buch
11.5.1 EPO Berlin-Buch Company Detail
11.5.2 EPO Berlin-Buch Business Overview
11.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Introduction
11.5.4 EPO Berlin-Buch Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.5.5 EPO Berlin-Buch Recent Development
11.6 Oncodesign
11.6.1 Oncodesign Company Detail
11.6.2 Oncodesign Business Overview
11.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Introduction
11.6.4 Oncodesign Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.6.5 Oncodesign Recent Development
11.7 Xentech
11.7.1 Xentech Company Detail
11.7.2 Xentech Business Overview
11.7.3 Xentech Patient-derived Xenograft (PDX) Models Introduction
11.7.4 Xentech Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.7.5 Xentech Recent Development
11.8 Envigo
11.8.1 Envigo Company Detail
11.8.2 Envigo Business Overview
11.8.3 Envigo Patient-derived Xenograft (PDX) Models Introduction
11.8.4 Envigo Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.8.5 Envigo Recent Development
11.9 Charles River Laboratories
11.9.1 Charles River Laboratories Company Detail
11.9.2 Charles River Laboratories Business Overview
11.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Introduction
11.9.4 Charles River Laboratories Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.9.5 Charles River Laboratories Recent Development
11.10 Pharmatest Services
11.10.1 Pharmatest Services Company Detail
11.10.2 Pharmatest Services Business Overview
11.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Introduction
11.10.4 Pharmatest Services Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.10.5 Pharmatest Services Recent Development
11.11 Urosphere
11.11.1 Urosphere Company Detail
11.11.2 Urosphere Business Overview
11.11.3 Urosphere Patient-derived Xenograft (PDX) Models Introduction
11.11.4 Urosphere Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.11.5 Urosphere Recent Development
11.12 MEDICILON
11.12.1 MEDICILON Company Detail
11.12.2 MEDICILON Business Overview
11.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Introduction
11.12.4 MEDICILON Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.12.5 MEDICILON Recent Development
11.13 Horizon Discovery
11.13.1 Horizon Discovery Company Detail
11.13.2 Horizon Discovery Business Overview
11.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Introduction
11.13.4 Horizon Discovery Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.13.5 Horizon Discovery Recent Development
11.14 Shanghai Model Organisms Center
11.14.1 Shanghai Model Organisms Center Company Detail
11.14.2 Shanghai Model Organisms Center Business Overview
11.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Introduction
11.14.4 Shanghai Model Organisms Center Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.14.5 Shanghai Model Organisms Center Recent Development
11.15 GemPharmatech
11.15.1 GemPharmatech Company Detail
11.15.2 GemPharmatech Business Overview
11.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Introduction
11.15.4 GemPharmatech Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.15.5 GemPharmatech Recent Development
11.16 LIDE Biotech
11.16.1 LIDE Biotech Company Detail
11.16.2 LIDE Biotech Business Overview
11.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Introduction
11.16.4 LIDE Biotech Revenue in Patient-derived Xenograft (PDX) Models Business (2018-2023)
11.16.5 LIDE Biotech Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
